A Randomized, Open-Label, Parallel-Group, Single Center study is to evaluate the Safety and Efficacy of a Novel Anti-Acne Nanoemulsion (NB-003)
Phase of Trial: Phase I
Latest Information Update: 07 May 2018
At a glance
- Drugs NB 003 (Primary) ; Benzoyl peroxide
- Indications Acne vulgaris; Gram-positive infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors BlueWillow Biologics
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 14 Sep 2010 Results were presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
- 13 Sep 2010 New trial record